Journal: Experimental and Therapeutic Medicine

Article Title: Construction of tissue-engineered bone using a bioreactor and platelet-rich plasma

doi: 10.3892/etm.2014.1774

Figure Lengend Snippet: Immunohistochemical analysis of vWF expression. Each rabbit was implanted at five different sites with β-TCP only (group A), BMSCs and β-TCP (group B), bioreactor-cultured BMSCs and β-TCP (group C), PRP-cultured BMSCs and β-TCP (group D), and bioreactor- and PRP-cultured BMSCs and β-TCP (group E), respectively. Three months following implantation, samples were collected from implanted rabbits (n=10). vWF expression was detected using immunohistochemistry. Cells with brown granules were considered positive cells. Expression of vWF was analyzed by immunohistochemistry. Representative immunohistochemical results from (A) group A, (B) group B, (C) group C, (D) group D and (E) group E (magnification, ×200). vWF, von Willebrand Factor; TCP, tricalcium phosphate; BMSCs, bone marrow mesenchymal stem cells; PRP, platelet-rich plasma.

Article Snippet: Hematoxylin and eosin (H&E), anti-cluster of differentiation (CD)31 antibody, anti-von Willebrand factor (vWF) antibody and 3,3′-diaminobenzidine (DAB) chromogenic reagent for immunohistochemistry were purchased from Boster Biological Technology Co., Ltd. (Wuhan, China).

Techniques: Immunohistochemical staining, Expressing, Cell Culture, Immunohistochemistry, Clinical Proteomics

Journal: Balkan Medical Journal

Article Title: Drug-eluting Vein Graft with Acetylsalicylic Acid-Ticagrelor-Unfractionated Heparin Complex Inhibits Early Graft Thrombosis

doi: 10.4274/balkanmedj.galenos.2020.2020.1.128

Figure Lengend Snippet: Von Willebrand factor (VWF) immunohistochemical staining of the study groups on the 1 st and 3 rd days. It was observed that VWF staining was lower in the locally acting drug group compared with that in the untreated and pluronic gel groups. From a general point of view, the lowest staining was observed with preparations containing acetylsalicylic acid + ticagrelor + unfractionated heparin (magnification 200x).

Article Snippet: Immunohistochemical staining was performed with the anti-rat von Willebrand factor (VWF) polyclonal antibody kit (Bioss, USA, lot no: AD071046) following the manufacturer’s instructions.

Techniques: Immunohistochemical staining, Staining

Journal: Cell

Article Title: A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity

doi: 10.1016/j.cell.2019.11.036

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Mouse monoclonal anti-VWF (C-12) , Santa Cruz Biotechnology , Cat# sc-365712; RRID: AB_10842026.

Techniques: Recombinant, Red Blood Cell Lysis, Modification, Saline, Activation Assay, Blocking Assay, Plasmid Preparation, Reverse Transcription, Sterility, Injection, Staining, Imaging, Enzyme-linked Immunosorbent Assay, Library Quantification, RNA Sequencing, Sequencing, Software, Adhesive, Cell Counting

Journal: Journal of Cellular and Molecular Medicine

Article Title: MAPK/ERK signalling mediates VEGF-induced bone marrow stem cell differentiation into endothelial cell

doi: 10.1111/j.1582-4934.2008.00266.x

Figure Lengend Snippet: Endothelial differentiation from MAPCs was suppressed by PD98059. (A) Transcript levels of endothelial cells (EC) and MAPC-specific genes detected by Q-RT-PCR. EC-specific transcripts of VE-cadherin, CD31 and von Willebrand factor (vWF) on the cells cultured with VEGF in the presence of PD98059 were decreased significantly versus cells cultured with VEGF alone for 14 days. Results shown are mean ± SD from three independent experiments. *: P < 0.05 compared with undifferentiated MAPCs (dO); **: P < 0.01 compared with undifferentiated MAPCs (dO); #: P < 0.05 compared with MAPCs cultured with VEGF alone for 14 days; ##: P < 0.01 compared with MAPCs cultured with VEGF alone for 14 days. PD, PD98059 50 μM. (β) Dil-Ac-LDL uptake in MAPCs cultured with VEGF in the absence (left panel) and presence (right panel) of PD98059 for 14 days. Dil-Ac-LDL uptake (Red) was inhibited in the cells cultured with VEGF in the presence of PD98059 as compared to VEGF alone. PD, PD98059 50 μM. Figures are representative of results obtained from 3 independent experiments.

Article Snippet: The preparations were then exposed to the primary antibodies: anti-von Willebrand factor Ab (Santa Cruz, CA, USA) at 1: 300 dilution, α-VE-cad-herin Ab (Santa Cruz) at 1:50 dilution, α-Flk-1 Ab (Santa Cruz) at 1: 50 dilution, α-N0S3 or eNOS (Santa Cruz) at 1: 50 dilution, or rabbit γ globulin (Jackson ImmunoResearch, West Grove, PA, USA) for 30 min. at 37°C.

Techniques: Reverse Transcription Polymerase Chain Reaction, Cell Culture

Journal: Frontiers in Cardiovascular Medicine

Article Title: Pro-inflammatory role of Wnt/β-catenin signaling in endothelial dysfunction

doi: 10.3389/fcvm.2022.1059124

Figure Lengend Snippet: Schematic diagram illustrating effect of inhibition of Wnt/β-catenin signaling on endothelial-platelet interaction in unchallenged and TNF-α-challenged cultured endothelial cells. Endothelial cells were treated with either 0.05% DMSO vehicle control or 25 μM iCRT in the presence or absence of 10 ng/mL recombinant human TNF-α stimulus for 18 h, then co-cultured with thrombin-activated platelets for 10 min. (A) Control: Unchallenged endothelial cells treated with 0.05% DMSO vehicle control. UL-vWF multimers remain stored in the Weibel-Palade bodies. (B) Control + iCRT-14: Unchallenged endothelial cells treated with 25 μM iCRT-14. UL-vWF multimers remain stored in the Weibel-Palade bodies. (C) TNF-α: TNF-α-challenged endothelial cells treated with 0.05% DMSO vehicle control. TNF-α stimulates release of UL-vWF from Weibel–Palade bodies. TNF-α-driven up-regulation in ADAMTS13 results in proteolytic cleavage of membrane-tethered UL-vWF; hence, TNF-α-stimulation does not promote endothelial-platelet interaction. (D) TNF-α + iCRT-14: TNF-α-challenged endothelial cells treated with 25 μM iCRT-14. TNF-α stimulates release of UL-vWF from Weibel–Palade bodies. Treatment with iCRT-14 blocks TNF-a-mediated up-regulation of ADAMTS13 thereby maintaining high levels of membrane-tethered UL-vWF; hence, platelet recruitment is enhanced. Acronyms: ADAMTS13 - a disintegrin-like and metalloprotease with thrombospondin type-1 repeats-13; TNF-α - tumor necrosis factor-a; UL-vWF - ultra-large von Willebrand factor.

Article Snippet: Primary antibodies included: anti-cleaved caspase-3 IgG (R&D Systems; MAB835), anti-NFκB p65 IgG (Cell Signaling Technology; 8242), anti-phospho-paxillin (Tyr118) IgG (Invitrogen; 44-722G), anti-VE-Cadherin IgG (Cell Signaling Technology; 2500), anti-von Willebrand factor IgG (Cell Signaling; 65707S), and anti-ZO-1 IgG (Abcam; ab221547).

Techniques: Inhibition, Cell Culture, Control, Recombinant, Membrane